Market Closed -
TEL AVIV STOCK EXCHANGE
15:31:09 02/05/2024 BST
|
5-day change
|
1st Jan Change
|
277.3
ILa
|
+3.97%
|
|
+6.98%
|
-7.51%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
39.24
|
170.9
|
71.25
|
26.24
|
41.96
|
37.69
|
-
|
-
|
Enterprise Value (EV)
1 |
39.24
|
170.9
|
71.25
|
26.24
|
41.96
|
37.69
|
37.69
|
37.69
|
P/E ratio
|
-7.51
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
164
x
|
76.6
x
|
15.7
x
|
7.44
x
|
2.22
x
|
1.2
x
|
0.63
x
|
EV / Revenue
|
-
|
164
x
|
76.6
x
|
15.7
x
|
7.44
x
|
2.22
x
|
1.2
x
|
0.63
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-1.91
x
|
-2.13
x
|
-2.81
x
|
-188
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
25,754
|
35,575
|
41,164
|
41,216
|
50,550
|
50,659
|
-
|
-
|
Reference price
2 |
5.256
|
15.44
|
5.375
|
2.235
|
2.998
|
2.773
|
2.773
|
2.773
|
Announcement Date
|
04/03/20
|
03/03/21
|
10/03/22
|
09/03/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
1.04
|
0.93
|
1.675
|
5.64
|
17
|
31.5
|
60
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-22.02
|
-17.72
|
-13.42
|
-0.2
|
EBIT
1 |
-
|
-24.81
|
-30.95
|
-26.94
|
-26.51
|
-22.92
|
-19.22
|
-7.4
|
Operating Margin
|
-
|
-2,385.96%
|
-3,328.28%
|
-1,608.42%
|
-470%
|
-134.85%
|
-61.03%
|
-12.33%
|
Earnings before Tax (EBT)
1 |
-
|
-26.17
|
-30.43
|
-29.75
|
-25.99
|
-22.92
|
-19.22
|
-7.4
|
Net income
1 |
-18.11
|
-23.37
|
-27.79
|
-26.64
|
-23.88
|
-20.92
|
-17.22
|
-5.4
|
Net margin
|
-
|
-2,247.5%
|
-2,988.49%
|
-1,590.33%
|
-423.39%
|
-123.09%
|
-54.68%
|
-9%
|
EPS
|
-0.7000
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/03/20
|
03/03/21
|
10/03/22
|
09/03/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.151
|
0.311
|
0.237
|
0.312
|
0.466
|
0.66
|
0.641
|
0.654
|
3.767
|
0.578
|
3.5
|
2.5
|
8
|
3
|
2.5
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-5.737
|
-6.453
|
-2.977
|
-6.852
|
-3.55
|
-5.325
|
-3.5
|
-5.35
|
-
|
EBIT
1 |
-8.556
|
-8.692
|
-8.055
|
-8.007
|
-7.097
|
-3.782
|
-6.796
|
-7.901
|
-4.183
|
-7.628
|
-4.85
|
-6.625
|
-4.8
|
-6.65
|
-
|
Operating Margin
|
-5,666.23%
|
-2,794.86%
|
-3,398.73%
|
-2,566.35%
|
-1,522.96%
|
-573.03%
|
-1,060.22%
|
-1,208.1%
|
-111.04%
|
-1,319.72%
|
-138.57%
|
-265%
|
-60%
|
-221.67%
|
-
|
Earnings before Tax (EBT)
1 |
-8.335
|
-8.09
|
-9.104
|
-9.716
|
-7.158
|
-3.776
|
-7.026
|
-7.757
|
-3.863
|
-7.341
|
-4.85
|
-6.625
|
-4.8
|
-6.65
|
-
|
Net income
1 |
-7.61
|
-7.371
|
-9.106
|
-8.821
|
-6.544
|
-2.998
|
-6.271
|
-7.023
|
-3.984
|
-6.601
|
-4.35
|
-6.125
|
-4.3
|
-6.15
|
-
|
Net margin
|
-5,039.74%
|
-2,370.1%
|
-3,842.19%
|
-2,827.24%
|
-1,404.29%
|
-454.24%
|
-978.32%
|
-1,073.85%
|
-105.76%
|
-1,142.04%
|
-124.29%
|
-245%
|
-53.75%
|
-205%
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
17/11/21
|
10/03/22
|
26/05/22
|
31/08/22
|
17/11/22
|
09/03/23
|
18/05/23
|
17/08/23
|
15/11/23
|
07/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
1.17
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
69.91%
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/03/20
|
03/03/21
|
10/03/22
|
09/03/23
|
07/03/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -7.51% | 35.95M | | +26.28% | 42.68B | | -3.99% | 42.4B | | +45.32% | 40.04B | | -6.20% | 28.31B | | +6.36% | 24.94B | | -21.47% | 18.96B | | +27.58% | 12.3B | | -2.75% | 11.95B | | -2.02% | 11.55B |
Other Biotechnology & Medical Research
|